A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), ... AZ's SGLT2 inhibitor Farxiga/Forxiga (dapagliflozin) ...

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, ...

See the latest AstraZeneca PLC ADR stock price (AZN:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Morningstar brands and products ...